Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a 39-year-old woman whose dermatomyositis-systemic lupus erythematosus overlap syndrome symptoms resolved after switching to tofacitinib.

This study observed that most patients with traction alopecia showed improved or stabilized hair loss with therapeutic counseling and adjunctive treatments, but follow-up was often inconsistent, highlighting the need for better awareness and management.

This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.

This study observed that insurance coverage for oral tofacitinib in alopecia areata patients was difficult to obtain, with 71% of patients ultimately not receiving approval despite the drug's efficacy as an off-label treatment.

This article describes the immunofluorescence tomography method to achieve high-resolution 3-D reconstruction of epithelial tissues and reports no clinical results.

This case report describes a man with trichorrhexis nodosa of the beard, who experienced symptomatic improvement after being advised to shave and avoid brushing, confirming the diagnosis.

This study found that recombinant human FGF9 expressed in Arabidopsis thaliana oil bodies significantly promoted the proliferation of NIH/3T3 cells.

This study found that the enzyme A20 helps regulate EDAR-induced NF-κB signaling in mice, preventing ectodermal abnormalities like disheveled hair and assuring proper skin and appendage development.

This study found that exogenous EGF inhibited hair follicle development and decreased follicle density in both Tabby and normal mice, suggesting interactions between EGF and the Ta peptide influence normal skin phenotype.

This case report found that oral tofacitinib treatment resulted in more than 90% hair regrowth in a 6-year-old with severe alopecia areata, with no relapse after dose reduction.

This study developed a foxn1-deficient Xenopus laevis model using CRISPR/Cas9, observing reduced T-cell markers and altered immune responses in tadpoles, providing a nonmammalian model for immunological research.

This study highlights that while there are no FDA- or ANVISA-approved treatments for children with alopecia areata, JAK inhibitors are emerging as a promising therapeutic option for this population.

In this study, researchers demonstrated that self-assembled gold nanoclusters with aptamers effectively deliver anti-NFκB aptamer drugs to inhibit hair follicle regeneration while being non-toxic to normal cells, offering a targeted treatment for hypertrichosis.

This study compared oral tofacitinib and methotrexate in treating moderate-to-severe alopecia areata, finding that tofacitinib was more effective at reducing SALT scores and improving scalp hair assessment PRO scores, though both treatments reduced psychological distress similarly without serious adverse effects.

This study suggests that systemic oxidative stress in female pattern hair loss may be related to NRF2 deficiency, and NRF2 activators might assist in treatment.

Frontal fibrosing alopecia can affect men's beards and leads to permanent hair loss.

This article discusses the FOXTM Procedure's potential impact on hair restoration surgery, noting that its long-term effects are not yet clear and reports no new clinical findings.

In this case report, a patient with early-stage Frontal Fibrosing Alopecia showed substantial improvement in follicular density and inflammation control after three monthly sessions of Botulinum Toxin Type A administered via microinfusion.

This study reports two siblings with severe combined immunodeficiency due to a mutation in the FOXN1 gene, characterized by T-cell immunodeficiency, alopecia totalis, and nail dystrophy.

This report presents the Taiwanese Dermatological Association's 2016 consensus on defining and managing skin toxicities from EGFR-TKI treatments, providing comprehensive guidelines for clinicians in Taiwan.

In this case report, a young female Indian patient with alopecia areata saw hair regrowth within 2 months of treatment with oral tofacitinib, with continued improvements over a 5-month period and no reported side effects.

This case report suggests that frontal fibrosing alopecia with nail involvement may be associated with lichen planus and improved with oral dutasteride due to an inflammatory reaction related to androgenetic alopecia.

This literature review reports that micro-needle radiofrequency is increasingly recognized in aesthetic medicine as a safe, effective treatment for various skin conditions, but further research is needed to optimize treatment parameters for the best outcomes.

Targeting immune pathways like JAK/STAT may help treat frontal fibrosing alopecia.

This chapter discusses aesthetic principles and surgical techniques for reconstructing a natural hairline in cases of thinning or loss of hair in the temporal area, but reports no new results.

In this six-year study of a Saudi cohort, oral tofacitinib showed favorable long-term effectiveness for patients with AA, with manageable adverse events requiring regular monitoring.

This study provides the most comprehensive review to date of published cases of frontal fibrosing alopecia, emphasizing a notable association with thyroid disease.

In this case report, a female patient with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvement in symptoms, including hair loss and lesions, after six months of treatment with tofacitinib, with no recurrence or adverse effects over a two-year follow-up.

This report details a refined hair transplantation method called direct no-shave follicular unit excision (DNS FUE), which avoids donor-site shaving and minimizes follicular trauma while yielding high patient satisfaction.

In this study, 40% of alopecia areata patients using topical 2% tofacitinib ointment achieved greater than 50% improvement in hair regrowth after six months, showing significant efficacy compared to controls, with no serious adverse effects reported.